Rivaroxaban CAS 366789-02-8 Dị Ọcha> 99.5% (HPLC) API Ogo dị elu
Ndị nrụpụta Rivaroxaban emetụtara ndị nrụpụta:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4- (4-Aminophenyl) morpholin-3-otu CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8
Aha Chemical | Rivaroxaban |
Ụdị okwu | (S) -Rivaroxaban;(S) -5-Chloro-N- ((2-oxo-3-- (4- (3-oxomorpholino) phenyl) -oxazolidin-5-yl) methyl) thiophene-2-carbox;BAY 59-7939 |
Nọmba CAS | 366789-02-8 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C19H18ClN3O5S |
Ibu molekụla | 435.88 |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ntụ ntụ ọcha ma ọ bụ ọ fọrọ nke nta ka ọ bụrụ ọcha |
njirimara A | Ntinye infrared nke Rivaroxaban dabara na ụkpụrụ ntụnye aka |
njirimara B | Oge njigide nke isi ọnụ ọgụgụ kachasị elu nke ngwọta ihe nlele kwekọrọ na nke usoro kwesịrị ekwesị ngwọta, dị ka enwetara na ịdị ọcha enantiomeric. |
Enantiomeric ịdị ọcha | RVX RC01: ≤0.15% |
Mmiri (KF) | ≤0.50% |
Sulfated Ash | ≤0.10% |
Ọla dị arọ | ≤20ppm |
Acid acid | ≤5000ppm |
Ihe ndị emetụtara (HPLC) | |
RVX RC02 | ≤0.15% |
RVX RC03 | ≤0.15% |
RVX RC04 | ≤0.15% |
RVX RC05 | ≤0.15% |
RVX RC06 | ≤0.15% |
RVX RC07 | ≤0.15% |
RVX RC08 | ≤0.15% |
Ọdịghị ọcha nke Onye Ọ bụla ọzọ | ≤0.10% |
Mgbakọta adịghị ọcha | <0.50% |
Ihe mgbaze fọdụrụ (GC) | |
Ethanol | ≤5000ppm |
Toluene | ≤890ppm |
Triethylamine | ≤320ppm |
Ụzọ ịdị ọcha / nyocha | > 99.5% (HPLC) (na-esighi ike) |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ojiji | API;Ọgwụ antithrombotic;Ihe mgbochi FXa |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri.
Rivaroxaban(CAS:366789-02-8) (Xarelto, Bayer) bụ ọgwụ mgbochi ọnụ.Ọ bụ ihe na-eme ihe ozugbo Xa inhibitor.A na-egosi Rivaroxaban maka 'ọgwụgwọ thrombosis miri emi na pulmonary embolism, na mgbochi nke thrombosis miri emi na-emegharị ugboro ugboro na pulmonary embolism na ndị okenye'.Maka ọgwụgwọ mbụ nke nnukwu akpa ume embolism, usoro akwadoro nke rivaroxaban bụ 15 mg ugboro abụọ kwa ụbọchị maka ụbọchị 21 mbụ na-esote 20 mg otu ugboro kwa ụbọchị maka ọgwụgwọ na-aga n'ihu na mgbochi nke thromboembolism venous ugboro ugboro.Ihe na-adịghị valvular Atrial Fibrillation (NVAF) iji gbochie ọrịa strok & embolism sistem.Ọgwụgwọ VTE siri ike & mgbochi nke VTE na-aga n'ihu [maka thrombosis miri emi (DVT) na embolism pulmonary (PE)].Mgbochi nke ihe omume thromboembolic venous (VTE) na ịwa ahụ ngbanwe hip ma ọ bụ ikpere (THR, TKR).